Transient Ischemic Attack Market Research Report - Global Forecast till 2027

Transient Ischemic Attack Market: Information by Diagnosis (Imaging Techniques), Treatment (Surgery and Drugs), Age Groups (0–18 years and above), End-User and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2027

ID: MRFR/Pharma/3590-CR | July 2019 | Region: Global | 226 pages

Transient Ischemic Attack Market Overview


The Transient Ischemic Attack Market is expected to register a CAGR of 6.08% and is anticipated to reach USD 2,268.5 Million by 2023. 


Transient ischemic stroke is also known as a mini-stroke. It leads to temporary blockage of blood flow to the brain. As it does not cause permanent damage, it is often ignored. The market is mainly driven by factors such as the rising prevalence of ischemia stroke cases, growing geriatric population, and increasing healthcare expenditure. However, the high cost of surgical procedures for the treatment of ischemic is likely to hinder the market growth.


Market Dynamics


The transient ischemic attack market is expected to exhibit exponential growth during the forecast period which is driven by all-rounder characteristics of the transient ischemic attack, increasing prevalence of chronic diseases such as cardiovascular diseases and cancer, and increase in the treatment of chronic diseases for the elderly population. It has been identified as one of the fastest emerging industries owing to the changing dynamics of the legal and regulatory framework and the intense competitive rivalry among an excess of public companies. As per the survey carried out by American Heart Association Report 2015, more than 17.9 million deaths were recorded in the US due to cardiovascular disorder, and the death rate is expected to grow to more than 23.6 Million by 2030. Besides, increasing healthcare expenditure has fueled the growth of the market. However, the growth of the market is restrained by the side effects of drugs for strokes and strict regulations for manufacturing medical devices for the treatment of strokes.


Transient Ischemic Attack Market Size, by Diagnosis, 2016 and 2023 (USD Million)  Transient Ischemic Attack Market


Source: MRFR Analysis


Segmentation


The transient ischemic attack has been segmented into diagnosis, treatment, age group, and end user. Based on the diagnosis, the market has been divided into imaging techniques and others. The imaging technique is further sub-segmented into computed tomography (CT) scan, carotid duplex scanning, magnetic resonance imaging, and echocardiography. The imaging technique segment accounted for a market value of USD 1004.4 Million in 2016. Based on treatment, the market has been segregated into surgery and drugs. The drugs segment is further sub-segmented into antithrombotic agents, antiplatelets, clopidogrel, aspirin, heparins, enoxaparin, dalteparin, fibrinolytic, and tenecteplase. By age groups, the market is further classified as  0–18 years, 19–40 years (Millennial), 41–60 years, and 60+ years. Based on end-user, the transient ischemic attack market has been bifurcated into hospitals & clinics, diagnostic centers, and research laboratories.


Key Players


The prominent players in the transient ischemic attack market are Koninklijke Philips NV (Netherlands), Stryker Corporation (US), Johnson & Johnson Services Inc (US), Boston Scientific Corporation (US), Sanofi (France), Bayer AG (Germany), Pfizer Inc (US), Siemens AG (US), F. Hoffmann-La Roche AG (Switzerland), GE Healthcare (UK), Penumbra Inc (California), Medtronic PLC (Ireland), Abbott Laboratories (US), Merck & Co., Inc (US), and Boehringer Ingelheim GmbH (Germany). 


Some of the key strategies followed by the players operating in the transient ischemic attack market were innovation, product development, acquisition, mergers, and expansion.


 Asia-Pacific Transient Ischemic Attack Market Share, By Country, 2016 (%)  Transient Ischemic Attack Market


Source: MRFR Analysis


Regional Analysis


The transient ischemic attack market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is estimated to dominate the transient ischemic attack market during the forecast period. This is attributed due to the well-developed technology, rising healthcare expenditure, and the presence of the leading players in the market. People in this region are very health conscious, which has led to increasing healthcare expenditure in this region.


Europe accounted for the second-largest market for transient ischemic attack. Rising investment in research & development, well-developed healthcare infrastructure, and increasing healthcare funds are some of the factors responsible for boosting the growth of the market in this region.


Asia-Pacific is projected to be the fastest-growing market due to the rising aging population, increasing healthcare expenditure, and the rising prevalence of cardiac disorders. In addition to this, improving healthcare facilities and rising economic growth is positively impacting the market growth in this region. Japan held the most significant market share of 32.97 % in 2016.


The market in the Middle East & Africa is expected to witness steady growth due to increasing investments in research & development, well-developed infrastructure, and advancement in technology.


Key Updates



  • In February 2018, Merck & Co. Inc acquired Viralytics Limited. This acquisition expanded Merck’s immunology pipeline.



  • In January 2018, Abbott entered into a definitive merger agreement by acquiring Alere Inc., a diagnostic device and service provider, for USD 56.00 per common share in cash.



  • In October 2018, Stryker Corporation announced the acquisition of VEXIM, a French medical device company. This acquisition enabled Stryker Corporation to increase its revenue in the future.



  • In August 2017, Sanofi completed the acquisition of Protein Sciences. This acquisition was a strategic fit for Sanofi Pasteur’s for developing new manufacturing technologies.



  • In May 2017, Boston Scientific Corporation announced the acquisition of Symetis SA, to focus on minimally invasive transcatheter aortic valve implantation (TAVI) devices.


Market Segmentation


Transient Ischemic Attack Market, by Diagnosis



  • Imaging Techniques

  • Computed Tomography (CT) scan

  • Carotid Duplex Scanning

  • Magnetic Resonance Imaging

  • Echocardiography            


Transient Ischemic Attack Market, by Treatment



  • Surgery

  • Drugs

  • Antithrombotic agents

  • Antiplatelets

  • Clopidogrel

  • Aspirin

  • Heparins

  • ENOXAPARIN

  • DALTEPARIN

  • Fibrinolytics

  • Tenecteplase


Transient Ischemic Attack Market, by Age Groups



  • 0–18 years

  • 19–40 years (Millennial)

  • 41–60 years

  • 60+ years


Transient Ischemic Attack Market, by End-User



  • Hospitals & Clinics

  • Diagnostic Centers

  • Research Laboratories


Transient Ischemic Attack Market, by Region



  • Americas


    • North America


      • US

      • Canada


    • Latin America




  • Europe


    • Western Europe


      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe


    • Eastern Europe




  • Asia-Pacific


    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific




  • Middle East & Africa


    • Middle East

    • Africa



Available Additional Customizations



  • Additional Companies


    • LivaNova PLC

    • EnteroMedics Inc.

    • ElectroCore Medical LLC

    • Cyberonics, Inc.

    • NeuroMetrix, Inc.

    • ImThera Medical

    • Inspire Medical Systems, Inc.

    • Nihon Kohden Corporation

    • Electrical Geodesics Inc.



Intended Audience



  • Medical device manufacturers and distributors

  • Government research organizations

  • Hospitals and clinics

  • Regulatory agencies

  • Contract research organizations

  • Academic institutes and universities



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


Transient ischemic attack market projected to grow at approximately 6.08% CAGR during the assessment period (2020-2027).

The valuation of the global transient ischemic attack market is estimated to increase to USD 2,268.5 MN by the end of 2023.

Rising need for better treatment due to the increasing prevalence of neurological disorders and increasing R&D investments in biotechnology and pharmaceutical sectors are major tailwinds pushing the growth of the global transient ischemic attack market.

North America holds the largest share in the global transient ischemic attack market, followed by Europe and the Asia Pacific, respectively.

EnteroMedics Inc. (U.S.), ElectroCore Medical LLC (U.S.), LivaNova PLC (U.K), Cyberonics, Inc. (US), NeuroMetrix, Inc.(U.S.), Boston Scientific Corporation (US), Inspire Medical Systems Inc.(U.S.), Electrical Geodesics Inc. (U.S.), ImThera Medical (U.S.), Nihon Kohden Corporation (Japan), Esaote (Italy), Masimo Corporation (U.S.), and Hologic (U.S.), are some of the top players operating in the global transient ischemic attack market.

1 Report Prologue

2 Executive Summary

3 Market Introduction

3.1 Definition 26

3.2 Scope Of Study 26

3.3 List Of Assumptions 26

3.4 Market Structure 27

4 Research Methodology

4.1 Research Process 29

4.2 Primary Research 30

4.3 Secondary Research 31

4.4 Market Size Estimation 32

4.5 Forecast Model 32

5 Market Dynamics

5.1 Introduction 34

5.2 Drivers 35

5.2.1 Increasing Preference For Minimally Invasive Procedures 35

5.2.2 Rising Prevalence Of Chronic Disorders 36

5.2.3 Improvement In Reimbursement Scenario 37

5.2.4 Rising Geriatric Population 38

5.3 Restraints 39

5.3.1 Rising Treatment Cost And Hospital Stay 39

5.3.2 Lack Of Skilled Physicians 40

5.4 Opportunities 41

5.4.1 New Advancements In Catheterization Devices 41

5.4.2 Guide Wire Assisted Surgery In Elderly Population 41

5.1 Mega Trends 41

5.1.1 Telemedicine 41

5.2 Macroeconomic Indicators 41

5.3 Technology Trends & Assessment 42

6 Market Factor Analysis

6.1 Porter’s Five Forces Model 44

6.1.1 Threat Of New Entrants 44

6.1.2 Bargaining Power Of Suppliers 44

6.1.3 Threat Of Substitutes 45

6.1.4 Bargaining Power Of Buyers 45

6.1.5 Intensity Of Rivalry 45

6.2 Supply Chain Analysis 46

6.2.1 Research &Development 46

6.2.2 Manufacturing 46

6.2.3 Distribution 46

6.2.4 Marketing & Sales 47

6.2.5 Post-Sales Monitoring 47

6.3 Demand & Supply: Gap Analysis 47

6.4 Pricing Analysis 47

6.5 Investment Feasibility Analysis 47

7 Global Transient Ischemic Attack Market, By Diagnosis

7.1 Introduction 49

7.2 Imaging Techniques 49

7.2.1 Computed Tomography (CT) Scan 51

7.2.2 Carotid Duplex Scanning 51

7.2.3 Magnetic Resonance Imaging 52

7.2.4 Echocardiography 52

8 Global Transient Ischemic Attack Market, By Treatment

8.1 Introduction 54

8.2 Surgery 54

8.3 Drugs 54

8.3.1 Surgery 55

8.3.2 Drugs 56

8.3.2.1 Antithrombotic Agents 56

8.3.2.2 Antiplatelets 56

8.3.2.3 Clopidogrel 57

8.3.2.4 Aspirin 57

8.3.2.5 Heparins 57

8.3.2.6 ENOXAPARIN 58

8.3.2.7 DALTEPARIN 58

8.3.2.8 Fibrinolytics 58

8.3.2.9 Tenecteplase 59

8.3.2.10 Alteplase 59

8.3.2.11 Antihypertensive Agents 59

8.3.2.12 Prazosin 60

8.3.2.13 Moxonidine 60

9 Global Transient Ischemic Attack Market, By Age Groups

9.1 Introduction 62

9.2 0–18 Years 62

9.3 19–40 Years (Millennial) 62

9.4 41–60 Years 62

9.5 60+ Years 63

9.5.1 0-18 Years 64

9.5.2 19-40 Years 65

9.5.3 41-60 Years 65

9.5.4 60+ Years 65

10 Global Transient Ischemic Attack Market, By End-User

10.1 Introduction 67

10.2 Hospitals & Clinics 67

10.3 Diagnostic Centers 67

10.4 Research Laboratories 68

10.4.1 Hospitals 69

10.4.2 Diagnostic Centers 70

10.4.3 Research Laboratories 70

11 Global Transient Ischemic Attack Market, By Region

11.1 Introduction 72

11.2 Americas 73

11.2.1 North America 78

11.2.1.1 U.S. 82

11.2.1.2 Canada 86

11.2.2 South America 90


11.3 Europe 94

11.3.1 Western Europe 99

11.3.1.1 Germany 103

11.3.1.2 France 107

11.3.1.3 U.K. 111

11.3.1.4 Italy 115

11.3.1.5 Spain 119

11.3.1.6 Rest Of Western Europe 123

11.3.2 Eastern Europe 127

11.4 Asia Pacific 131

11.4.1 Asia Pacific 132

11.4.2 Japan 136

11.4.3 China 140

11.4.4 India 144

11.4.5 Australia 148

11.4.6 Republic Of Korea 152

11.4.7 Rest Of Asia Pacific 156

11.5 The Middle East & Africa 160

11.5.1 Middle East And Africa 161

11.5.2 United Arab Emirates 164

11.5.3 Saudi Arabia 168

11.5.4 Rest Of Middle East & Africa 172

12 Competitive Landscape

12.1 Company Market Share Analysis 177

12.1.1 Introduction 177

12.2 Company Share Analysis 178

12.3 Recent Developments, 2013–2018 179

13 Company Profiles

13.1 Koninklijke Philips N.V. 184

13.1.1 Company Overview 184

13.1.2 Financial Overview 184

13.1.3 Products Offering 185

13.1.4 Key Developments 185

13.1.5 SWOT Analysis 185

13.1.6 Key Strategy 186

13.2 Stryker Corporation 187

13.2.1 Company Overview 187

13.2.2 Financial Overview 187

13.2.3 Products Offering 188

13.2.4 Key Developments 188

13.2.5 SWOT Analysis 189

13.2.6 Key Strategy 189

13.3 Johnson & Johnson Services Inc. 190

13.3.1 Company Overview 190

13.3.2 Financial Overview 190

13.3.3 Products Offering 191

13.3.4 Key Developments 191

13.3.5 SWOT Analysis 192

13.3.6 Key Strategy 192

13.4 Boston Scientific Corporation 193

13.4.1 Company Overview 193

13.4.2 Financial Overview 193

13.4.3 Products Offering 194

13.4.4 Key Developments 195

13.4.5 SWOT Analysis 195

13.4.6 Key Strategy 195

13.5 Sanofi 196

13.5.1 Company Overview 196

13.5.2 Financial Overview 196

13.5.3 Products Offering 197

13.5.4 Key Developments 197

13.5.5 SWOT Analysis 197

13.5.6 Key Strategy 197

13.6 Bayer AG 198

13.6.1 Company Overview 198

13.6.2 Financial Overview 198

13.6.3 Products Offering 199

13.6.4 Key Developments 199

13.6.5 SWOT Analysis 199

13.6.6 Key Strategy 199

13.7 Pfizer Inc. 200

13.7.1 Company Overview 200

13.7.2 Financial Overview 200

13.7.3 Products Offering 201

13.7.4 Key Developments 201

13.7.5 SWOT Analysis 201

13.7.6 Key Strategy 201

13.8 Siemens AG 202

13.8.1 Company Overview 202

13.8.2 Financial Overview 202

13.8.3 Products Offering 203

13.8.4 Key Developments 203

13.8.5 SWOT Analysis 203

13.8.6 Key Strategy 203

13.9 F. Hoffmann-La Roche AG 204

13.9.1 Company Overview 204

13.9.2 Financial Overview 204

13.9.3 Products Offering 205

13.9.4 Key Developments 205

13.9.5 SWOT Analysis 205

13.9.6 Key Strategy 205

13.10 GE Healthcare 206

13.10.1 Company Overview 206

13.10.2 Financial Overview 206

13.10.3 Products Offering 207

13.10.4 Key Developments 207

13.10.5 SWOT Analysis 207

13.10.6 Key Strategy 207

13.11 Penumbra, Inc. 208

13.11.1 Company Overview 208

13.11.2 Financial Overview 208

13.11.3 Products Offering 209

13.11.4 Key Developments 209

13.11.5 SWOT Analysis 209

13.11.6 Key Strategy 210

13.12 Medtronic PLC 211

13.12.1 Company Overview 211

13.12.2 Financial Overview 211

13.12.3 Products Offering 212

13.12.4 Key Developments 212

13.12.5 SWOT Analysis 212

13.12.6 Key Strategy 213

13.13 Abbott Laboratories 214

13.13.1 Company Overview 214

13.13.2 Financial Overview 214

13.13.3 Products Offering 215

13.13.4 Key Developments 215

13.13.5 SWOT Analysis 216

13.13.6 Key Strategy 216

13.14 Merck & Co., Inc. 217

13.14.1 Company Overview 217

13.14.2 Financial Overview 217

13.14.3 Products Offering 218

13.14.4 Key Developments 218

13.14.5 SWOT Analysis 218

13.14.6 Key Strategy 218

13.15 Boehringer Ingelheim GmbH 219

13.15.1 Company Overview 219

13.15.2 Financial Overview 219

13.15.3 Products Offering 220

13.15.4 Key Developments 220

13.15.5 SWOT Analysis 220

13.15.6 Key Strategy 220

14 Conclusion

14.1 Key Findings 222

14.1.1 CEO’s Viewpoint 222

14.1.2 Unmet Needs 222

14.1.3 Key Companies To Watch 222

14.1.4 Prediction 222

15 Appendix

15.1 Discussion Blue Print 224

15.2 References 225

16 List Of Tables

TABLE 1 MARKET SYNOPSIS 24

TABLE 2 LIST OF ASSUMPTIONS 26

TABLE 3 PRIMARY INTERVIEWS 30

TABLE 4 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 50

TABLE 5 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUES, 2020–2027 (USD MILLION) 50

TABLE 6 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY COMPUTED TOMOGRAPHY (CT) SCAN,

2020–2027 (USD MILLION) 51

TABLE 7 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY CAROTID DUPLEX SCANNING,

2020–2027 (USD MILLION) 51

TABLE 8 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY MAGNETIC RESONANCE IMAGING,

2020–2027 (USD MILLION) 52

TABLE 9 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY ECHOCARDIOGRAPHY,

2020–2027 (USD MILLION) 52

TABLE 10 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 55

TABLE 11 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY SURGERY, 2020–2027 (USD MILLION) 55

TABLE 12 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 56

TABLE 13 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUG, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 56

TABLE 14 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 56

TABLE 15 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIPLATELETS, BY CLOPIDOGREL, 2020–2027 (USD MILLION) 57

TABLE 16 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIPLATELETS, BY ASPIRIN, 2020–2027 (USD MILLION) 57

TABLE 17 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 57

TABLE 18 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HEPARINS, BY ENOXAPARIN, 2020–2027 (USD MILLION) 58

TABLE 19 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HEPARINS, BY DALTEPARIN, 2020–2027 (USD MILLION) 58

TABLE 20 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 58

TABLE 21 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR FIBRINOLYTICS, BY TENECTEPLASE, 2020–2027 (USD MILLION) 59

TABLE 22 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR FIBRINOLYTICS, BY ALTEPLASE 2020–2027 (USD MILLION) 59

TABLE 23 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 59

TABLE 24 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIHYPERTENSIVE AGENTS, BY PRAZOSIN,

2020–2027 (USD MILLION) 60

TABLE 25 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIHYPERTENSIVE AGENTS, BY MOXONIDINE,

2020–2027 (USD MILLION) 60

TABLE 26 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUPS, 2020–2027 (USD MILLION) 63

TABLE 27 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 0-18 YEARS, 2020–2027 (USD MILLION) 64

TABLE 28 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 19-40 YEARS, 2020–2027 (USD MILLION) 65

TABLE 29 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 41-60 YEARS, 2020–2027 (USD MILLION) 65

TABLE 30 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 60+ YEARS, 2020–2027 (USD MILLION) 65

TABLE 31 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 68

TABLE 32 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 69

TABLE 33 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION) 70

TABLE 34 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR RESEARCH LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 70

TABLE 35 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY REGION, 2020–2027 (USD MILLION) 72

TABLE 36 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY REGION, 2020–2027 (USD MILLION) 73

TABLE 37 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 74

TABLE 38 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 74

TABLE 39 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 74

TABLE 40 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 75

TABLE 41 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 75

TABLE 42 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 75

TABLE 43 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 76

TABLE 44 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 76

TABLE 45 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 76

TABLE 46 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 77

TABLE 47 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 77

TABLE 48 NORTH AMERICA: TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 78

TABLE 49 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 78

TABLE 50 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,

2020–2027 (USD MILLION) 79

TABLE 51 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 79

TABLE 52 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 79

TABLE 53 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,

2020–2027 (USD MILLION) 80

TABLE 54 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 80

TABLE 55 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 80

TABLE 56 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 81

TABLE 57 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,

2020–2027 (USD MILLION) 81

TABLE 58 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 81

TABLE 59 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 82

TABLE 60 U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 82

TABLE 61 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 82

TABLE 62 U.S. TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 83

TABLE 63 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 83

TABLE 64 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS 2020–2027 (USD MILLION) 83

TABLE 65 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 84

TABLE 66 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 84

TABLE 67 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 84

TABLE 68 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 85

TABLE 69 U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 85

TABLE 70 U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 85

TABLE 71 CANADA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 86

TABLE 72 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 86

TABLE 73 CANADA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 86

TABLE 74 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 87

TABLE 75 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 87

TABLE 76 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 87

TABLE 77 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 88

TABLE 78 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 88

TABLE 79 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 88

TABLE 80 CANADA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 89

TABLE 81 CANADA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 89

TABLE 82 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 90

TABLE 83 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,

2020–2027 (USD MILLION) 90

TABLE 84 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 90

TABLE 85 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 91

TABLE 86 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,

2020–2027 (USD MILLION) 91

TABLE 87 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 91

TABLE 88 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 92

TABLE 89 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 92

TABLE 90 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,

2020–2027 (USD MILLION) 92

TABLE 91 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 93

TABLE 92 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 93

TABLE 93 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 94

TABLE 94 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 95

TABLE 95 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 95

TABLE 96 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 95

TABLE 97 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 96

TABLE 98 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 96

TABLE 99 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 96

TABLE 100 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 97

TABLE 101 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 97

TABLE 102 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 97

TABLE 103 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 98

TABLE 104 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 98

TABLE 105 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 99

TABLE 106 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,

2020–2027 (USD MILLION) 99

TABLE 107 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 99

TABLE 108 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 100

TABLE 109 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,

2020–2027 (USD MILLION) 100

TABLE 110 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 100

TABLE 111 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 101

TABLE 112 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 101

TABLE 113 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,

2020–2027 (USD MILLION) 101

TABLE 114 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 102

TABLE 115 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 102

TABLE 116 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 103

TABLE 117 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 103

TABLE 118 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 103

TABLE 119 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 104

TABLE 120 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 104

TABLE 121 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 104

TABLE 122 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 105

TABLE 123 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 105

TABLE 124 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 105

TABLE 125 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 106

TABLE 126 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 106

TABLE 127 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 107

TABLE 128 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 107

TABLE 129 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 107

TABLE 130 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 108

TABLE 131 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 108

TABLE 132 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 108

TABLE 133 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 109

TABLE 134 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 109

TABLE 135 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 109

TABLE 136 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 110

TABLE 137 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 110

TABLE 138 U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 111

TABLE 139 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 111

TABLE 140 U.K TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 111

TABLE 141 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 112

TABLE 142 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 112

TABLE 143 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 112

TABLE 144 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 113

TABLE 145 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION) 113

TABLE 146 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 113

TABLE 147 U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 114

TABLE 148 U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 114

TABLE 149 ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 115

TABLE 150 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 115

TABLE 151 ITALY TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 115

TABLE 152 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 116

TABLE 153 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS 2020–2027 (USD MILLION) 116

TABLE 154 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 116

TABLE 155 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 117

TABLE 156 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 117

TABLE 157 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 117

TABLE 158 ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 118

TABLE 159 ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 118

TABLE 160 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 119

TABLE 161 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 119

TABLE 162 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 119

TABLE 163 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 120

TABLE 164 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 120

TABLE 165 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 120

TABLE 166 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 121

TABLE 167 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 121

TABLE 168 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 121

TABLE 169 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 122

TABLE 170 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 122

TABLE 171 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 123

TABLE 172 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,

2020–2027 (USD MILLION) 123

TABLE 173 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 123

TABLE 174 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 124

TABLE 175 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,

2020–2027 (USD MILLION) 124

TABLE 176 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 124

TABLE 177 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 125

TABLE 178 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 125

TABLE 179 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,

2020–2027 (USD MILLION) 125

TABLE 180 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 126

TABLE 181 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 126

TABLE 182 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 127

TABLE 183 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,

2020–2027 (USD MILLION) 127

TABLE 184 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 127

TABLE 185 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 128

TABLE 186 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,

2020–2027 (USD MILLION) 128

TABLE 187 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 128

TABLE 188 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 129

TABLE 189 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 129

TABLE 190 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,

2020–2027 (USD MILLION) 129

TABLE 191 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 130

TABLE 192 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 130

TABLE 193 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 131

TABLE 194 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 132

TABLE 195 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 132

TABLE 196 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 132

TABLE 197 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 133

TABLE 198 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 133

TABLE 199 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 133

TABLE 200 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 134

TABLE 201 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 134

TABLE 202 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,

2020–2027 (USD MILLION) 134

TABLE 203 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 135

TABLE 204 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 135

TABLE 205 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 136

TABLE 206 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 136

TABLE 207 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 136

TABLE 208 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 137

TABLE 209 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 137

TABLE 210 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 137

TABLE 211 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 138

TABLE 212 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 138

TABLE 213 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 138

TABLE 214 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 139

TABLE 215 JAPAN TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 139

TABLE 216 CHINA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 140

TABLE 217 CHINA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 140

TABLE 218 CHINA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 140

TABLE 219 CHINA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 141

TABLE 220 CHINA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 141

TABLE 221 CHINA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 141

TABLE 222 CHINA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 142

TABLE 223 CHINA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 142

TABLE 224 CHINA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 142

TABLE 225 CHINA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 143

TABLE 226 CHINA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 143

TABLE 227 INDIA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 144

TABLE 228 INDIA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 144

TABLE 229 INDIA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 144

TABLE 230 INDIA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 145

TABLE 231 INDIA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 145

TABLE 232 INDIA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 145

TABLE 233 INDIA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 146

TABLE 234 INDIA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 146

TABLE 235 INDIA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 146

TABLE 236 INDIA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 147

TABLE 237 INDIA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 147

TABLE 238 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 148

TABLE 239 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 148

TABLE 240 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 148

TABLE 241 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 149

TABLE 242 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 149

TABLE 243 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 149

TABLE 244 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 150

TABLE 245 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 150

TABLE 246 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 150

TABLE 247 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 151

TABLE 248 AUSTRALIA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 151

TABLE 249 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 152

TABLE 250 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,

2020–2027 (USD MILLION) 152

TABLE 251 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 152

TABLE 252 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 153

TABLE 253 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,

2020–2027 (USD MILLION) 153

TABLE 254 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 153

TABLE 255 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 154

TABLE 256 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 154

TABLE 257 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,

2020–2027 (USD MILLION) 154

TABLE 258 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 155

TABLE 259 REPUBLIC OF KOREA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 155

TABLE 260 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 156

TABLE 261 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,

2020–2027 (USD MILLION) 156

TABLE 262 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 156

TABLE 263 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 157

TABLE 264 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,

2020–2027 (USD MILLION) 157

TABLE 265 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 157

TABLE 266 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 158

TABLE 267 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 158

TABLE 268 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,

2020–2027 (USD MILLION) 158

TABLE 269 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 159

TABLE 270 REST OF ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 159

TABLE 271 MIDDLE EAST & AFRICA TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 160

TABLE 272 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 161

TABLE 273 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,

2020–2027 (USD MILLION) 161

TABLE 274 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 161

TABLE 275 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 162

TABLE 276 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,

2020–2027 (USD MILLION) 162

TABLE 277 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 162

TABLE 278 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 163

TABLE 279 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 163

TABLE 280 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,

2020–2027 (USD MILLION) 163

TABLE 281 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 164

TABLE 282 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 164

TABLE 283 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 164

TABLE 284 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE,

2020–2027 (USD MILLION) 165

TABLE 285 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 165

TABLE 286 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 165

TABLE 287 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS,

2020–2027 (USD MILLION) 166

TABLE 288 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS,

2020–2027 (USD MILLION) 166

TABLE 289 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS,

2020–2027 (USD MILLION) 166

TABLE 290 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS,

2020–2027 (USD MILLION) 167

TABLE 291 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS,

2020–2027 (USD MILLION) 167

TABLE 292 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 167

TABLE 293 UNITED ARAB EMIRATES TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 168

TABLE 294 SAUDI ARABIA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 168

TABLE 295 SAUDI ARABIA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 168

TABLE 296 SAUDI ARABIA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 169

TABLE 297 SAUDI ARABIA TRANSIENT ISCHEMIC ATTACK M

17 List Of Figures

FIGURE 1 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET: MARKET STRUCTURE 27

FIGURE 2 RESEARCH PROCESS OF MRFR 29

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 32

FIGURE 4 DRIVERS & RESTRAINTS: GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET 34

FIGURE 5 PORTERS FIVE FORCES MODEL 44

FIGURE 6 SUPPLY CHAIN: TRANSIENT ISCHEMIC ATTACK MARKET 46

FIGURE 7 GLOBAL TRANSIENT ISCHEMIC ATTAK MARKET, BY DIAGNOSIS, 2020 (% SHARE) 49

FIGURE 8 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020 TO 2027 (USD MILLION) 50

FIGURE 9 GLOBAL TRANSIENT ISCHEMIC ATTAK MARKET, BY TREATMENT 2020 (% SHARE) 54

FIGURE 10 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY TREATMENT, 2020 TO 2027 (USD MILLION) 55

FIGURE 11 GLOBAL TRANSIENT ISCHEMIC ATTAK MARKET, BY AGE GROUP 2020 (% SHARE) 63

FIGURE 12 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUPS, 2020 TO 2027 (USD MILLION) 64

FIGURE 13 GLOBAL TRANSIENT ISCHEMIC ATTAK MARKET, BY END USER 2020 (% SHARE) 68

FIGURE 14 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020 TO 2027 (USD MILLION) 69

FIGURE 15 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY REGION, 2020 TO 2027 (USD MILLION) 72

FIGURE 16 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY REGION, 2020 (%) 73

FIGURE 17 NORTH AMERICA: TRANSIENT ISCHEMIC ATTACK MARKET SHARE, BY COUNTRY, 2020 (% SHARE) 78

FIGURE 18 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020 (%) 94

FIGURE 19 ASIA PACIFIC TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020 (%) 131

FIGURE 20 MIDDLE EAST & AFRICA TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020 (%) 160

FIGURE 21 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, COMPANY SHARE ANALYSIS 2020 (%) 177

FIGURE 22 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET COMPETITIVE LANDSCAPE (%) 178

Key Market Players Harnessing Breakthrough Technologies to Differentiate From Competitors


The global transient ischemic attack market is at present dominated by a few major players.  Majority of the companies in this market have adopted to utilize the strategy of acquisition for developing their market share.


Among the market leaders is Johnson & Johnson Inc. which is an American multinational company dealing in medical devices, pharmaceutical and consumer packaged goods manufacturing. It is also engaged in manufacturing, marketing, and selling of consumer healthcare products across the globe. The company's major focus areas in the pharmaceutical segment include immunology, neuroscience, infectious disease, and oncology. It has around 250 subsidiary companies which operate in 60 countries and its products are sold in over 175 countries.


Abbott Laboratories is one of the market leaders because of its strong foothold in the particular space. The U.S.-based company focuses on discovery, development, manufacture, and sale of healthcare products. In August 2017, the company had made an agreement with Roxwood Medical for product distribution in the U.S. In the same year, Abbott also acquired St. Jude Medical to strengthen its medical device leadership along with innovations in cardiovascular and neuromodulators categories.

Hoffmann-La Roche Ltd. which is the second largest medical device company holds a share of 12% in the market as of the year 2016. The company has a vast brand image, broad product portfolio, and strong distribution networks around the globe. The firm also develops and manufactures pharmaceutical, medical and diagnostic products. Roche is also well known for their technological and therapeutic innovations.

The other prominent players in the market include Boston Scientific Corporation, Koninklijke Philips N.V, Abbott Laboratories Inc., Medtronic plc., Stryker Corporation, Siemens AG, Johnson & Johnson Services Inc., Sanofi SA, Bayer AG, Pfizer Inc., F. Hoffmann-La Roche AG, GE Healthcare, Penumbra, Inc., Abbott Laboratories, Merck & Co., Inc., and Boehringer Ingelheim GmbH.